Evidence map›Paper›PMID 29581452›Full record

ArticleScientific reports2018

Semi-Automated Biomarker Discovery from Pharmacodynamic Effects on EEG in ADHD Rodent Models.

Tatsuya Yokota, Zbigniew R Struzik, Peter Jurica, Masahito Horiuchi, Shuichi Hiroyama, Junhua Li, Yuji Takahara, Koichi Ogawa, Kohei Nishitomi, Minoru Hasegawa and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Tatsuya YokotaRIKEN Brain Science Institute, Hirosawa, Wako, Saitama, Japan.
Zbigniew R StruzikRIKEN Brain Science Institute, Hirosawa, Wako, Saitama, Japan. zbigniew.struzik@riken.jp.ORCID 0000-0002-1352-8897
Peter JuricaRIKEN Brain Science Institute, Hirosawa, Wako, Saitama, Japan.
Masahito HoriuchiSHIONOGI & Co., Ltd., Futaba, Toyonaka, Osaka, Japan.
Shuichi HiroyamaSHIONOGI & Co., Ltd., Futaba, Toyonaka, Osaka, Japan.
Junhua LiRIKEN Brain Science Institute, Hirosawa, Wako, Saitama, Japan.
Yuji TakaharaSHIONOGI & Co., Ltd., Futaba, Toyonaka, Osaka, Japan.
Koichi OgawaSHIONOGI & Co., Ltd., Futaba, Toyonaka, Osaka, Japan. kouichi.ogawa@shionogi.jp.
Kohei NishitomiSHIONOGI & Co., Ltd., Futaba, Toyonaka, Osaka, Japan.
Minoru HasegawaSHIONOGI & Co., Ltd., Futaba, Toyonaka, Osaka, Japan.
Andrzej CichockiRIKEN Brain Science Institute, Hirosawa, Wako, Saitama, Japan.
Futaba (Japan) · JPRIKEN Center for Brain Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We propose a novel semi-automatic approach to design biomarkers for capturing pharmacodynamic effects induced by pharmacological agents on the spectral power of electroencephalography (EEG) recordings. We apply this methodology to investigate the pharmacodynamic effects of methylphenidate (MPH) and atomoxetine (ATX) on attention deficit/hyperactivity disorder (ADHD), using rodent models. We inject the two agents into the spontaneously hypertensive rat (SHR) model of ADHD, the Wistar-Kyoto rat (WKY), and the Wistar rat (WIS), and record their EEG patterns. To assess individual EEG patterns quantitatively, we use an integrated methodological approach, which consists of calculating the mean, slope and intercept parameters of temporal records of EEG spectral power using a smoothing filter, outlier truncation, and linear regression. We apply Fisher discriminant analysis (FDA) to identify dominant discriminants to be heuristically consolidated into several new composite biomarkers. Results of the analysis of variance (ANOVA) and t-test show benefits in pharmacodynamic parameters, especially the slope parameter. Composite biomarker evaluation confirms their validity for genetic model stratification and the effects of the pharmacological agents used. The methodology proposed is of generic use as an approach to investigating thoroughly the dynamics of the EEG spectral power.

Indexed as

BiomarkersElectroencephalographyAnimalsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityDisease Models, AnimalHumansLinear ModelsMethylphenidateRatsRats, Inbred SHRAtomoxetine HydrochlorideBiomarkersMethylphenidate

Identifiers

PMID29581452
PMCPMC5980101
OpenAlexW2805815913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.